Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors
Rhea-AI Summary
Aprea Therapeutics (Nasdaq: APRE) presented updated Phase 1 data for oral WEE1 inhibitor APR-1051 at ASCO 2026, showing early monotherapy activity and manageable tolerability in advanced solid tumors.
The ACESOT-1051 study reported partial responses, stable disease, dose-proportional PK and ongoing expansion into uterine serous carcinoma and platinum-resistant ovarian cancer, with dose escalation and backfill completion expected in Q2 2027.
AI-generated analysis. Not financial advice.
Positive
- Two endometrial cancer patients achieved partial responses on APR-1051 monotherapy
- Six additional patients experienced stable disease across multiple tumor types
- APR-1051 well tolerated; 54% treatment-related adverse events, mostly Grade 1–2
- Dose-proportional exposure and ~18-hour half-life support once-daily dosing
- Enrollment expanding to at least 50 uterine serous carcinoma patients
- Clear timeline with dose escalation and backfill completion targeted for Q2 2027
Negative
- ACESOT-1051 remains an early Phase 1 trial with 28 patients enrolled
- Treatment-related adverse events occurred in 54% of patients (mainly nausea, fatigue)
- Key dose escalation and backfill milestones not expected to complete until Q2 2027
News Market Reaction – APRE
On the day this news was published, APRE declined 8.59%, reflecting a notable negative market reaction. Argus tracked a trough of -20.6% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $11.05M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
APRE was down 4.07% while momentum-screened biotech peers like BOLT and PCSA were up about 5.5–7.4%, pointing to stock-specific dynamics around this update.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 21 | ASCO abstract acceptance | Positive | -7.5% | ASCO 2026 abstract acceptance for early APR-1051 Phase 1 results. |
| Mar 30 | APR-1051 PR update | Positive | +8.2% | Confirmed partial response and additional disease control at up to 220 mg APR-1051. |
| Oct 15 | ATRN-119 RP2D set | Neutral | -1.3% | RP2D of 1,100 mg for ATRN-119 and pivot toward combination strategies. |
| Jun 25 | Early WEE1 data | Positive | +10.1% | Promising preclinical and early APR-1051 data with anti-proliferative effects and stable disease. |
| Dec 11 | ATRN-119 BID dosing | Neutral | +3.3% | Introduction of twice-daily ATRN-119 dosing at 550 mg BID in ABOYA-119 trial. |
Clinical trial updates have usually seen aligned reactions, with 4 of 5 past same-tag events moving in the expected direction; the ASCO abstract acceptance in Apr 2026 was the notable negative divergence.
Over the past 18 months, Aprea has steadily built its clinical narrative around WEE1 inhibitor APR-1051 and ATR inhibitor ATRN-119. Earlier updates reported dose escalation up to 220 mg for APR-1051 with partial responses and stable disease, and established an RP2D of 1,100 mg once daily for ATRN-119. Multiple clinical data releases in 2025–2026 triggered mixed but mostly constructive price reactions. Today’s ASCO 2026 Phase 1 poster fits this progression as a deeper readout of ACESOT-1051 efficacy, tolerability, and enrollment expansion plans.
Historical Comparison
In the past five clinical-trial headlines, APRE’s average move was about 2.54%, with mostly aligned reactions to WEE1/ATR updates. This ASCO Phase 1 dataset extends that sequence of efficacy and dose-escalation milestones.
Clinical updates have progressed from early APR-1051 disease-stabilization signals through a confirmed partial response at 220 mg, while ATRN-119 moved from once-daily dosing to BID and RP2D determination, culminating in broader ASCO 2026 Phase 1 data.
Regulatory & Risk Context
An effective Form S-3 filed on Apr 22, 2026 registers 74,349,426 common shares for resale tied to pre-funded and common warrants from the March 2026 private placement. Aprea will not receive proceeds from these resales but may receive cash if warrants are exercised, and exercises are constrained by 4.99%/9.99% beneficial ownership blockers.
Market Pulse Summary
The stock moved -8.6% in the session following this news. A negative reaction despite encouraging Phase 1 activity would fit prior instances where positive trial or conference news, including the ASCO abstract acceptance on Apr 21, 2026, preceded downside moves. The update confirms partial responses, stable disease, and manageable tolerability, but the market may focus on overhangs from warrant-linked share registrations and the long runway to completing dose escalation and backfill, targeted for Q2 2027.
Key Terms
phase 1 medical
wee1 inhibitor medical
dose-limiting toxicity medical
maximum tolerated dose medical
recommended phase 2 dose medical
pharmacokinetics medical
biomarker-selected medical
AI-generated analysis. Not financial advice.
- Presentation highlights early clinical activity from ACESOT-1051, including partial responses and stable disease in patients across multiple tumor types
- Manageable tolerability confirmed across cohorts
- Patient expansion into uterine serous carcinoma and platinum-resistant ovarian cancer underway; dose escalation and backfill expansion expected to complete Q2 2027
DOYLESTOWN, Pa., June 01, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, announces the presentation of a poster “Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)” on May 30 at the American Society of Clinical Oncology (ASCO) 2026 annual meeting, taking place in Chicago, Illinois.
APR-1051 is an orally bioavailable, potent, and selective small molecule WEE1 inhibitor with in vivo anti-tumor activity in several cancer models. It exhibits low off-target inhibition of PLK kinases (PLK1, PLK2, PLK3), a property that differentiates it from prior WEE1 inhibitors and may contribute to an improved safety profile. ACESOT-1051 is the ongoing first-in-human Phase 1 study evaluating once-daily APR-1051 in advanced solid tumors harboring cancer-associated gene alterations.
“We are pleased to have the opportunity to present the updated ACESOT-1051 data to the oncology community at this year’s ASCO meeting,” said Gene Kennedy, M.D., Chief Medical Advisor of Aprea. “The partial responses and disease stabilizations we have observed in this heavily pretreated, biomarker-selected patient population reinforce our confidence in APR-1051’s differentiated profile and the potential of our precision medicine strategy. With enrollment now expanding into uterine serous carcinoma and platinum-resistant ovarian cancer, dose escalation and backfill expansion is on track to complete in the second quarter of 2027. Importantly, we believe that we are on a clear path to generating the data that will demonstrate APR-1051's potential."
ACESOT-1051: A Biomarker-Focused, Phase 1 Trial of Oral WEE1 Inhibitor, APR-1051
The poster (Abstract #3107) provides an updated summary of ACESOT-1051 with a data cutoff of May 6, 2026. Key highlights from the presentation include:
- Study objectives: The primary objective is to characterize the safety profile, dose-limiting toxicity (DLT), maximum tolerated dose or maximum administered dose, and recommended Phase 2 dose (RP2D) of APR-1051. Secondary objectives include characterization of the PK of APR-1051 and assessment of preliminary efficacy of APR-1051
- Clinical activity: Two patients with endometrial cancers have achieved partial responses (“PR”). Six additional patients achieved stable disease, including those with colorectal cancer, HPV+ head and neck squamous cell carcinoma, and endometrial cancer.
- Tolerability: APR-1051 has been well tolerated across all dose levels. Treatment-related adverse events were reported in
54% of patients, with nausea (36% ) and fatigue (14% ) the most common, nearly all Grade 1 or 2. - Pharmacokinetics: APR-1051 exposure is dose-proportional with a half-life of approximately 18 hours, supporting once-daily dosing.
- Study status: 28 patients with advanced solid tumors harboring specific cancer-associated gene alterations have been enrolled at doses from 10 mg to 300 mg once daily. Dose escalation is ongoing, with enrollment currently underway in the 300 mg cohort (dose level 9). Aprea is expanding enrollment to include at least 50 patients with uterine serous carcinoma as well as patients with cyclin E-overexpressing, platinum-resistant ovarian cancer. Completion of dose escalation and backfill expansion is anticipated in the second quarter of 2027.
For more information on ACESOT-1051, refer to ClinicalTrials.gov NCT06260514. A copy of the poster will be available on Aprea’s corporate website, later today.
About Aprea Therapeutics
Aprea is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. The Company is pioneering a new approach to treat cancer by exploiting vulnerabilities associated with cancer cell mutations. This approach was developed to kill tumors while minimizing the effect on normal, healthy cells. Aprea’s technology has potential applications across multiple cancer types, enabling it to target a range of tumors, including ovarian, endometrial, colorectal and head and neck squamous cell carcinoma. The Company’s lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small molecule ATR inhibitor, both in clinical development for solid tumor indications. For more information, please visit www.aprea.com.
The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
Forward-Looking Statement
Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our study analyses, clinical trials, regulatory submissions, and projected cash position. We may, in some cases use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team and on information currently available to management that involve risks, potential changes in circumstances, assumptions, and uncertainties. All statements contained in this press release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize, and achieve market acceptance of our current and planned products and services, our research and development efforts, including timing considerations and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward-looking statements are subject to risks and uncertainties including, without limitation, risks related to the success, timing, and cost of our ongoing clinical trials and anticipated clinical trials for our current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of our ongoing clinical trials, our understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from our clinical development programs, and our ability to predict clinical outcomes based on such preclinical and early clinical results, and the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to update such forward-looking statements for any reason, except as required by law.
Investor Contact:
Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com
Media Contact:
Sean Naughton Ph.D.
Russo Partners, LLC
sean.naughton@russopartnersllc.com
(858) 717-2310
